ClearPoint Neuro (CLPT) Competitors

$11.13 -0.51 (-4.38%)

Closing price 04:00 PM Eastern

Extended Trading

$11.22 +0.09 (+0.79%)

As of 07:55 PM Eastern

CLPT vs. ENOV, PRCT, PLSE, CDRE, and INSP

Should you buy ClearPoint Neuro stock or one of its competitors? MarketBeat compares ClearPoint Neuro with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ClearPoint Neuro include Enovis (ENOV), PROCEPT BioRobotics (PRCT), Pulse Biosciences (PLSE), Cadre (CDRE), and Inspire Medical Systems (INSP). These companies are all part of the "medical equipment" industry.

How does ClearPoint Neuro compare to Enovis?

Enovis (NYSE:ENOV) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability and earnings.

Enovis presently has a consensus target price of $45.17, suggesting a potential upside of 78.81%. ClearPoint Neuro has a consensus target price of $18.00, suggesting a potential upside of 61.73%. Given Enovis' stronger consensus rating and higher possible upside, research analysts plainly believe Enovis is more favorable than ClearPoint Neuro.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enovis	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Enovis has a net margin of -49.92% compared to ClearPoint Neuro's net margin of -71.57%. Enovis' return on equity of 10.32% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enovis	-49.92%	10.32%	4.57%
ClearPoint Neuro	-71.57%	-140.96%	-36.98%

98.5% of Enovis shares are owned by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are owned by institutional investors. 2.9% of Enovis shares are owned by company insiders. Comparatively, 6.9% of ClearPoint Neuro shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Enovis has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market. Comparatively, ClearPoint Neuro has a beta of 1.29, indicating that its share price is 29% more volatile than the broader market.

ClearPoint Neuro has lower revenue, but higher earnings than Enovis. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enovis	$2.25B	0.65	-$1.18B	-$19.88	N/A
ClearPoint Neuro	$36.97M	9.03	-$25.54M	-$1.01	N/A

In the previous week, ClearPoint Neuro had 2 more articles in the media than Enovis. MarketBeat recorded 5 mentions for ClearPoint Neuro and 3 mentions for Enovis. Enovis' average media sentiment score of 0.57 beat ClearPoint Neuro's score of -0.04 indicating that Enovis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enovis	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ClearPoint Neuro	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Enovis beats ClearPoint Neuro on 12 of the 17 factors compared between the two stocks.

How does ClearPoint Neuro compare to PROCEPT BioRobotics?

ClearPoint Neuro (NASDAQ:CLPT) and PROCEPT BioRobotics (NASDAQ:PRCT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

PROCEPT BioRobotics has a net margin of -31.82% compared to ClearPoint Neuro's net margin of -71.57%. PROCEPT BioRobotics' return on equity of -27.70% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ClearPoint Neuro	-71.57%	-140.96%	-36.98%
PROCEPT BioRobotics	-31.82%	-27.70%	-20.29%

ClearPoint Neuro has a beta of 1.29, meaning that its stock price is 29% more volatile than the broader market. Comparatively, PROCEPT BioRobotics has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market.

ClearPoint Neuro has higher earnings, but lower revenue than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than ClearPoint Neuro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ClearPoint Neuro	$36.97M	9.03	-$25.54M	-$1.01	N/A
PROCEPT BioRobotics	$308.05M	4.81	-$95.57M	-$1.82	N/A

30.1% of ClearPoint Neuro shares are held by institutional investors. Comparatively, 89.5% of PROCEPT BioRobotics shares are held by institutional investors. 6.9% of ClearPoint Neuro shares are held by insiders. Comparatively, 17.4% of PROCEPT BioRobotics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

ClearPoint Neuro currently has a consensus price target of $18.00, indicating a potential upside of 61.73%. PROCEPT BioRobotics has a consensus price target of $41.45, indicating a potential upside of 59.38%. Given ClearPoint Neuro's higher probable upside, equities research analysts clearly believe ClearPoint Neuro is more favorable than PROCEPT BioRobotics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
PROCEPT BioRobotics	2 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, PROCEPT BioRobotics had 4 more articles in the media than ClearPoint Neuro. MarketBeat recorded 9 mentions for PROCEPT BioRobotics and 5 mentions for ClearPoint Neuro. PROCEPT BioRobotics' average media sentiment score of 1.01 beat ClearPoint Neuro's score of -0.04 indicating that PROCEPT BioRobotics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ClearPoint Neuro	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PROCEPT BioRobotics	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

PROCEPT BioRobotics beats ClearPoint Neuro on 10 of the 16 factors compared between the two stocks.

How does ClearPoint Neuro compare to Pulse Biosciences?

Pulse Biosciences (NASDAQ:PLSE) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

Pulse Biosciences has a beta of 1.63, suggesting that its share price is 63% more volatile than the broader market. Comparatively, ClearPoint Neuro has a beta of 1.29, suggesting that its share price is 29% more volatile than the broader market.

Pulse Biosciences presently has a consensus target price of $30.00, suggesting a potential upside of 17.14%. ClearPoint Neuro has a consensus target price of $18.00, suggesting a potential upside of 61.73%. Given ClearPoint Neuro's higher probable upside, analysts clearly believe ClearPoint Neuro is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

77.0% of Pulse Biosciences shares are held by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are held by institutional investors. 74.0% of Pulse Biosciences shares are held by insiders. Comparatively, 6.9% of ClearPoint Neuro shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Pulse Biosciences has a net margin of 0.00% compared to ClearPoint Neuro's net margin of -71.57%. Pulse Biosciences' return on equity of -86.67% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	N/A	-86.67%	-73.61%
ClearPoint Neuro	-71.57%	-140.96%	-36.98%

In the previous week, Pulse Biosciences and Pulse Biosciences both had 5 articles in the media. Pulse Biosciences' average media sentiment score of 0.84 beat ClearPoint Neuro's score of -0.04 indicating that Pulse Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulse Biosciences	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ClearPoint Neuro	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ClearPoint Neuro has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than ClearPoint Neuro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$350K	5,064.19	-$72.78M	-$1.10	N/A
ClearPoint Neuro	$36.97M	9.03	-$25.54M	-$1.01	N/A

Summary

Pulse Biosciences beats ClearPoint Neuro on 7 of the 13 factors compared between the two stocks.

How does ClearPoint Neuro compare to Cadre?

ClearPoint Neuro (NASDAQ:CLPT) and Cadre (NYSE:CDRE) are both small-cap medical equipment companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

In the previous week, Cadre had 7 more articles in the media than ClearPoint Neuro. MarketBeat recorded 12 mentions for Cadre and 5 mentions for ClearPoint Neuro. Cadre's average media sentiment score of 0.29 beat ClearPoint Neuro's score of -0.04 indicating that Cadre is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ClearPoint Neuro	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cadre	4 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ClearPoint Neuro has a beta of 1.29, indicating that its share price is 29% more volatile than the broader market. Comparatively, Cadre has a beta of 1.32, indicating that its share price is 32% more volatile than the broader market.

30.1% of ClearPoint Neuro shares are owned by institutional investors. Comparatively, 44.0% of Cadre shares are owned by institutional investors. 6.9% of ClearPoint Neuro shares are owned by insiders. Comparatively, 30.1% of Cadre shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

ClearPoint Neuro presently has a consensus price target of $18.00, suggesting a potential upside of 61.73%. Cadre has a consensus price target of $39.75, suggesting a potential upside of 36.12%. Given ClearPoint Neuro's higher possible upside, analysts clearly believe ClearPoint Neuro is more favorable than Cadre.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Cadre	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.43

Cadre has a net margin of 5.80% compared to ClearPoint Neuro's net margin of -71.57%. Cadre's return on equity of 12.39% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ClearPoint Neuro	-71.57%	-140.96%	-36.98%
Cadre	5.80%	12.39%	5.08%

Cadre has higher revenue and earnings than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Cadre, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ClearPoint Neuro	$36.97M	9.03	-$25.54M	-$1.01	N/A
Cadre	$610.31M	2.05	$44.14M	$0.89	32.81

Summary

Cadre beats ClearPoint Neuro on 15 of the 17 factors compared between the two stocks.

How does ClearPoint Neuro compare to Inspire Medical Systems?

Inspire Medical Systems (NYSE:INSP) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, valuation and media sentiment.

Inspire Medical Systems presently has a consensus target price of $85.00, suggesting a potential upside of 103.38%. ClearPoint Neuro has a consensus target price of $18.00, suggesting a potential upside of 61.73%. Given Inspire Medical Systems' higher possible upside, equities research analysts clearly believe Inspire Medical Systems is more favorable than ClearPoint Neuro.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inspire Medical Systems	2 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.10
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Inspire Medical Systems has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market. Comparatively, ClearPoint Neuro has a beta of 1.29, suggesting that its stock price is 29% more volatile than the broader market.

Inspire Medical Systems has a net margin of 14.33% compared to ClearPoint Neuro's net margin of -71.57%. Inspire Medical Systems' return on equity of 10.35% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inspire Medical Systems	14.33%	10.35%	8.81%
ClearPoint Neuro	-71.57%	-140.96%	-36.98%

Inspire Medical Systems has higher revenue and earnings than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Inspire Medical Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inspire Medical Systems	$911.98M	1.32	$145.42M	$4.49	9.31
ClearPoint Neuro	$36.97M	9.03	-$25.54M	-$1.01	N/A

94.9% of Inspire Medical Systems shares are held by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are held by institutional investors. 2.2% of Inspire Medical Systems shares are held by company insiders. Comparatively, 6.9% of ClearPoint Neuro shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, ClearPoint Neuro had 2 more articles in the media than Inspire Medical Systems. MarketBeat recorded 5 mentions for ClearPoint Neuro and 3 mentions for Inspire Medical Systems. Inspire Medical Systems' average media sentiment score of 0.06 beat ClearPoint Neuro's score of -0.04 indicating that Inspire Medical Systems is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inspire Medical Systems	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ClearPoint Neuro	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Inspire Medical Systems beats ClearPoint Neuro on 11 of the 16 factors compared between the two stocks.

Get ClearPoint Neuro News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLPT vs. The Competition

Export

Metric	ClearPoint Neuro	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$349.08M	$6.75B	$6.25B	$12.28B
Dividend Yield	N/A	1.76%	2.80%	5.30%
P/E Ratio	-11.02	49.87	20.86	25.24
Price / Sales	9.03	71.35	549.88	74.17
Price / Cash	N/A	24.43	27.48	37.27
Price / Book	11.24	6.54	9.67	6.63
Net Income	-$25.54M	$158.81M	$3.56B	$335.41M
7 Day Performance	-9.59%	-1.03%	-1.91%	-1.83%
1 Month Performance	-5.60%	-5.70%	-2.65%	-1.16%
1 Year Performance	-15.55%	-3.78%	31.17%	28.31%

ClearPoint Neuro Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLPT ClearPoint Neuro	1.931 of 5 stars	$11.13 -4.4%	$18.00 +61.7%	-11.7%	$349.08M	$36.97M	N/A	110	Earnings Report
ENOV Enovis	4.6098 of 5 stars	$24.75 -6.7%	$45.17 +82.5%	-32.6%	$1.53B	$2.28B	N/A	7,802
PRCT PROCEPT BioRobotics	4.0941 of 5 stars	$26.45 +4.1%	$41.45 +56.7%	-55.0%	$1.45B	$308.05M	N/A	430	Positive News
PLSE Pulse Biosciences	2.3733 of 5 stars	$19.08 flat	$30.00 +57.2%	+42.8%	$1.30B	$350K	N/A	140	High Trading Volume
CDRE Cadre	3.9007 of 5 stars	$31.37 +5.1%	$43.00 +37.1%	-15.2%	$1.28B	$610.31M	29.32	2,533

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLPT) was last updated on 5/18/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ClearPoint Neuro (CLPT) Competitors

CLPT vs. ENOV, PRCT, PLSE, CDRE, and INSP

How does ClearPoint Neuro compare to Enovis?

Summary

How does ClearPoint Neuro compare to PROCEPT BioRobotics?

Summary

How does ClearPoint Neuro compare to Pulse Biosciences?

Summary

How does ClearPoint Neuro compare to Cadre?

Summary

How does ClearPoint Neuro compare to Inspire Medical Systems?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLPT vs. The Competition

ClearPoint Neuro Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ClearPoint Neuro (CLPT) Competitors

CLPT vs. ENOV, PRCT, PLSE, CDRE, and INSP

How does ClearPoint Neuro compare to Enovis?

Do analysts prefer ENOV or CLPT?

Is ENOV or CLPT more profitable?

Do insiders and institutionals hold more shares of ENOV or CLPT?

Which has more volatility & risk, ENOV or CLPT?

Which has stronger earnings and valuation, ENOV or CLPT?

Does the media favor ENOV or CLPT?

Summary

How does ClearPoint Neuro compare to PROCEPT BioRobotics?

Is CLPT or PRCT more profitable?

Which has more risk & volatility, CLPT or PRCT?

Which has stronger earnings and valuation, CLPT or PRCT?

Do insiders & institutionals hold more shares of CLPT or PRCT?

Do analysts prefer CLPT or PRCT?

Does the media favor CLPT or PRCT?

Summary

How does ClearPoint Neuro compare to Pulse Biosciences?

Which has more volatility & risk, PLSE or CLPT?

Do analysts recommend PLSE or CLPT?

Do insiders & institutionals have more ownership in PLSE or CLPT?

Is PLSE or CLPT more profitable?

Does the media refer more to PLSE or CLPT?

Which has preferable valuation & earnings, PLSE or CLPT?

Summary

How does ClearPoint Neuro compare to Cadre?

Does the media favor CLPT or CDRE?

Which has more volatility and risk, CLPT or CDRE?

Do insiders and institutionals have more ownership in CLPT or CDRE?

Do analysts recommend CLPT or CDRE?

Is CLPT or CDRE more profitable?

Which has preferable earnings and valuation, CLPT or CDRE?

Summary

How does ClearPoint Neuro compare to Inspire Medical Systems?

Do analysts rate INSP or CLPT?

Which has more risk & volatility, INSP or CLPT?

Is INSP or CLPT more profitable?

Which has preferable earnings & valuation, INSP or CLPT?

Do insiders and institutionals hold more shares of INSP or CLPT?

Does the media prefer INSP or CLPT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLPT vs. The Competition

ClearPoint Neuro Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools